LinkedIn image ad examples

Op tijd handelen is ook een daad van liefde. Luxe wonen voor ouderen met dementie en/of een fysieke zorgvraag. Beoordeeld met een 9,3 op Zorgkaart NL

A clear takeaway from ERS 2026 was the vital role the healthcare industry has to play in climate change. In the case of inhalers, propellants are our single largest source of greenhouse gas emissions. But changing them is our biggest lever. That's why Chiesi is transitioning to a next-generation, low global warming potential, non-PFAS propellant. This reduces the carbon footprint of its pMDIs by up to 90%, bringing them in line with DPI products.

Inpatient, Day Surgery, Outpatient and Diagnostics and Imaging. See how you compare across all four in our 2026 Global Private Healthcare Industry Benchmarking Report.

Patient experience often decides who leads in private healthcare. Our 2026 report gives you clear, global NPS benchmarks — so you can see where you stand, spot the gaps that matter, and act on them.

One case. Multiple layers of evidence. One unified interpretation platform. Geneyx is expanding its multiomics capabilities by integrating EpiSign Inc. METRIC into Geneyx Analysis, enabling DNA methylation episignatures to be analyzed alongside genomic, phenotypic, and clinical evidence in a single platform. For laboratories and geneticists, this means: A more complete view of complex rare disease cases Integrated genomic and epigenomic interpretation Support for microarray, short-read, and long-read technologies Greater insight from 5-base sequencing workflows Faster, more confident clinical decision-making With access to more than 300 disease-associated episignatures, EpiSign METRIC brings over ten years of curated episignature expertise and reference data directly into Illumina 5-base, PacBio HiFi, and Oxford Nanopore Technologies for sequencing workflows. As rare disease diagnostics evolve beyond single-modality analysis, Geneyx continues to advance its vision of a unified multiomics interpretation platform where every relevant layer of evidence contributes to better answers for every case. #Geneyx #EpiSign #RareDisease #Genomics #Epigenomics #MultiOmics #ClinicalGenomics #LongReadSequencing #PrecisionMedicine

🧪 Free Hytest antibodies and antigens — test before you invest. Complimentary evaluation samples are available for commercial IVD manufacturers and assay developers across the Middle East and South Asia. 🔍 Evaluate them in your own assay before committing resources to scale-up. ✅ Six clinical areas: Cardiac markers, Infectious diseases, Fertility & pregnancy, Inflammation, Thyroid diseases and Tumor markers. 📅 15 September – 15 November 2026. 📦 The material is free of charge; you cover shipping and any local charges.

Biobeat Webinar | Beyond the Cuff: What 24-Hour Blood Pressure Monitoring Reveals About Hypertension Few people have shaped preventive cardiology like Arthur Agatston, MD, FACC - creator of the Agatston Score and a longtime voice for catching cardiovascular risk before it becomes an event. We're honored he's joining us live for a one-hour session on the importance of accurately diagnosing hypertension. A single BP measurement at a clinic tells you what blood pressure was doing in one moment, in one setting. It doesn't tell you what happens overnight, during a stressful commute, or in the hours before a patient wakes up - the windows where cardiovascular risk often hides. In this webinar, Dr. Agatston will cover where traditional hypertension management falls short and how cuffless ABPM is changing the way the condition is diagnosed and treated. Monday, October 12 | 4:00 PM ET Live online - register to attend or receive the recording Save your spot: https://lnkd.in/dqBmkBxA

Japan - a land of tradition, precision, and fascinating duality. On the one hand, it can feel like living in the future. On the other, centuries-old traditions and social codes remain deeply rooted in everyday life. We bring that same attention to detail and precision to everything we do, helping keep flocks safe, healthy, and thriving. Want a little taste of Japan? Head to the first comment and try making your own chicken katsu.

𝗔𝗜 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲: 𝗙𝗿𝗼𝗺 𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗠𝗼𝗱𝗲𝗹𝘀 𝘁𝗼 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗜𝗺𝗽𝗮𝗰𝘁 Effective symptom management remains one of the most important aspects of cancer care. Beyond improving quality of life, timely identification and management of symptoms can help reduce avoidable healthcare use and better support patients throughout their survivorship journey. A recent scoping review by Wang et al. examined 41 studies exploring the emerging role of AI in cancer symptom management among adult cancer survivors. The findings highlight a wide range of applications, from symptom detection and monitoring to clinical decision support, personalized care recommendations, patient education, and counselling. But perhaps the most interesting message lies beyond the technology itself. As the authors note, the evidence base remains heterogeneous, and many AI tools have yet to undergo robust external validation. This need for evaluation is not unique to AI. All healthcare interventions are expected to generate evidence before being implemented in clinical practice. As AI becomes more prevalent in healthcare, its performance, safety, clinical utility, and impact on outcomes must likewise be systematically assessed. Real-world evidence (RWE) has been instrumental in evaluating the performance of medical interventions in everyday clinical practice over the past decade, and it will likely be equally valuable for AI in healthcare. By complementing laboratory data on AI model performance, RWE can offer critical insights into safety, equity, clinical utility, and effectiveness across broader populations. However, AI also poses challenges that differ from those of traditional medical interventions. AI tools may evolve over time and interact with clinical workflows in complex ways. Evaluating their real-world performance may therefore require adapting established RWE approaches to account for factors such as model evolution, implementation, and ongoing performance monitoring. As AI continues to shape healthcare, we will be following developments in this field with great interest and sharing perspectives on how technology and real-world evidence can work together to improve patient care. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗽𝗮𝗽𝗲𝗿 𝗵𝗲𝗿𝗲! https://lnkd.in/d2ByRpNZ #AI #Oncology #CancerCare #SymptomManagement #RealWorldEvidence

Taking a peptide into a pen or pre-filled syringe? The concentration you need may be more than the molecule can handle. Aggregation, viscosity and solubility limits tend to show up late, when changing course costs the most time and material. The Peptide Development Checklist helps you catch them first: • 15 peptide-specific risks across 4 areas • Why each one matters and what to check • Device fit, multi-dosing and liquid vs lyophilized decisions Use it before your next formulation decision, or share it with your CMC team.

🌟 WORLD FIRST: High-Purity Porphyra-334 Analytical Standard Now Available! 🌟 💡 We are thrilled to announce a major breakthrough for natural product chemistry and cosmetic research: Extrasynthese is launching the world’s first commercially available analytical standard for Porphyra-334! https://lnkd.in/emvMPScK 👉 As a prominent Mycosporine-like Amino Acid (MAA) derived from red algae, Porphyra-334 is renowned for its exceptional natural photoprotective and antioxidant properties. 👉 Shinorine is also available: https://lnkd.in/eysYarUf Key Applications & Research Fields: ☀️ Natural UV-A Protection & Sunscreen Formulation: Characterization and quantification of sustainable, eco-friendly sunscreens. 🌿 Cosmeceuticals & Anti-Aging: Study of cellular protection against photo-aging and oxidative stress. 🧪 Marine Biotechnology & QC: Precise chromatographic identification and profiling (HPLC / LC-UV-MS). 🤝 Ensure total accuracy, repeatability, and confidence in your analytical workflows with our high-purity reference material. 📌 Be among the first to integrate this innovative standard into your lab. 🔎 Discover our catalog or contact our technical team for data sheets and orders: https://lnkd.in/eRXGwUuf #MarineBiotechnology #MAAs #Porphyra334 #Cosmetics #Photoprotection #AnalyticalChemistry #Extrasynthese #Innovation

Inspire airway stimulation is a proven effective therapy for the treatment of obstructive sleep apnoea (OSA). Unilateral, respiratory synchronous stimulation of the hypoglossal nerve (HGNS) keeps the airways open during sleep. ___ This information is intended for healthcare professionals only. Individual treatment results may vary. For further information about the intended purpose, safety and performance of Inspire therapy, visit https://lnkd.in/eY8bDQJB.

Z przyjemnością informujemy, że Krzysztof Nojszewski dołączył do Chiesi Poland jako General Manager🤝. Krzysztof wnosi ponad 25 lat doświadczenia w branży farmaceutycznej, obejmującego m.in. zarządzanie działalnością komercyjną, market access, transformację organizacyjną oraz rozwój talentów. Przez wiele lat pełnił stanowiska kierownicze, ostatnio jako Country Value & Access Head w Polsce. Wcześniej był również General Managerem w Słowenii i Bułgarii, odpowiadając za rozwój biznesu i organizacji oraz zarządzanie zespołami międzyfunkcyjnymi. W swojej pracy Krzysztof stawia na partnerski styl przywództwa, rozwój pracowników, strategiczne podejście do biznesu oraz tworzenie wartości dla pacjentów i interesariuszy systemu ochrony zdrowia. Życzymy powodzenia w nowej roli i wielu udanych wspólnych projektów!

🇮🇹 GALEN-N is now at CPHI Milan 2026! The event has officially begun, and our team is ready to connect with industry professionals, potential clients and partners from around the world. 🔬 One of our key highlights is Galantamine Hydrobromide — a naturally sourced active pharmaceutical ingredient manufactured under strict quality requirements, with a strong focus on precision, consistency and traceability. Our pharmaceutical portfolio also includes Esculin and Glaucine Hydrobromide, alongside botanical extracts, essential oils and other natural ingredients. 🤝 Are you attending CPHI Milan? We would be delighted to meet you in person, discuss your needs and explore opportunities for future collaboration. 📍 Fiera Milano, Milan, Italy 📅 October 6–8, 2026 📌 Stand 2J52 Come and meet the GALEN-N team. Let's connect and explore new opportunities together!

Working with a low-dose peptide? At these concentrations, small losses add up fast. Peptide can adsorb to vials, tubing and filters, so recovery drops and your results stop reflecting what is in the formulation. High potency adds a second problem: exposure limits that shape your lab setup. The Peptide Development Checklist covers what to check early: • Material compatibility and process losses • Degradation pathways and analytical characterization • OEL/OEB, containment and safe handling 15 risks in total, with what to consider for each.

Servizio Express: la diagnosi genetica in sole 2 settimane In situazioni cliniche acute, una risposta genetica tempestiva può fare la differenza. Il Servizio Express offre un referto genetico completo in sole 2 settimane, fornendo rapidamente informazioni utili a supportare le decisioni cliniche e la gestione del paziente con sospetta malattia rara. Perché scegliere il Servizio Express? - Confermare o escludere rapidamente una diagnosi genetica - Identificare o escludere varianti genetiche associate a malattie rare in tempi compatibili con le esigenze del percorso decisionale clinico. Orientare tempestivamente la gestione del paziente - Disporre di risultati genetici confermati per supportare decisioni relative a interventi chirurgici, terapie farmacologiche specifiche o invii urgenti a specialisti. Ridurre i tempi di attesa e l’incertezza - Offrire al paziente e alla sua famiglia una risposta in tempi rapidi, in un momento in cui la chiarezza diagnostica è particolarmente importante. Per informazioni sul percorso Express e sulle indicazioni cliniche, contatti il nostro team: https://lnkd.in/dhq652hG

What a great turnout for our third edition of the #NeuroBiomarkerTalks! 🙌 It was an insightful session, and the Q&A brought valuable perspectives that enriched the discussion. A sincere thank‑you to our speakers, Dr. Daniel Alcolea and Prof. Dr. Jonathan Schott, for sharing their expertise and contributing to a highly engaging webinar. Missed it? You can watch the full recording here 🎥 https://lnkd.in/evbmMtGg Feel free to reach out to our team at the Fujirebio Neuro Center of Excellence, we’re here to support your next steps. Explore our full portfolio here: https://lnkd.in/dVFGAQqK Looking forward to staying connected! 🤝

EuroStim, eines der größten Register der letzten Jahre zur Hypoglossusnerv-Stimulation in Europa, ist gestartet! Dieses Projekt ist das erste seiner Art: Eine Langzeitstudie zur Batterielaufzeit (mit einer Nachbeobachtungszeit von rund 10 Jahren pro Patient), die weitere Erkenntnisse und Evidenz zur Inspire Therapie liefern wird. __ Diese Informationen sind nur für den professionellen Gebrauch bestimmt. Für Patienten mit mittelschwerer bis schwerer Obstruktiver Schlafapnoe bei medizinischer Eignung. Weitere Informationen unter https://lnkd.in/eY8bDQJB.

What a great turnout for our third edition of the #NeuroBiomarkerTalks! 🙌 It was an insightful session, and the Q&A brought valuable perspectives that enriched the discussion. A sincere thank‑you to our speakers, Dr. Daniel Alcolea and Prof. Dr. Jonathan Schott, for sharing their expertise and contributing to a highly engaging webinar. Missed it? You can watch the full recording here 🎥 https://lnkd.in/evbmMtGg Feel free to reach out to our team at the Fujirebio Neuro Center of Excellence, we’re here to support your next steps. Explore our full portfolio here: https://lnkd.in/eUUeEnXA Looking forward to staying connected! 🤝

Pod koniec sierpnia w Olsztynie odbyło się kolejne z naszych cyklicznych spotkań, wypełnione intensywnymi warsztatami, inspirującymi szkoleniami oraz wymianą doświadczeń między zespołami. Podczas tych kilku dni nie zabrakło również czasu na mniej formalne spotkania i wspólną zabawę. To świetna okazja do integracji, budowania relacji między pracownikami różnych działów i lepszego poznawania się poza codziennym rytmem pracy. W Chiesi zależy nam na tym, aby nasi pracownicy byli na bieżąco z tym, co dzieje się w organizacji, mieli przestrzeń do rozwoju i wymiany wiedzy, a jednocześnie budowali poczucie wspólnoty. Takie spotkania łączą wszystkie te elementy i pozwalają nam być bliżej siebie jako zespołowi🙌.

A post-translational protein feature, H3K27ac, emerged as a key predictor of ADC response, revealing biology invisible to spatial transcriptomics. In a recent study of HER2-positive breast cancer treated with the ADC SHR-A1811, researchers at Fudan University found that tumors achieving a pathological complete response contained higher proportions of H3K27ac-positive epithelial cells. Because H3K27ac is a post-translational histone modification, it reflects a functional protein state that could not be directly detected through RNA expression alone. Using Imaging Mass Cytometry™ (IMC™) technology, researchers gained a more complete view of the biology associated with ADC response and resistance. Their findings showed that therapeutic response was influenced not only by tumor cell biology, but also by features of the tumor microenvironment. ➡️ H3K27ac-positive tumor cells were associated with response ➡️ Collagen-rich, fibroblast-dense microenvironments were associated with resistance ➡️ Spatial features derived from IMC were used to develop an ADC efficacy prediction model and investigate combination strategies designed to improve ADC response For ADC researchers, these findings highlight the value of looking beyond target expression alone to understand the functional states and microenvironment features that shape therapeutic efficacy. Read more in our latest article: https://lnkd.in/g7fdAQGe #ADC #AntibodyDrugConjugates #SpatialProteomics #IMC #SpatialBiology #CancerResearch #DrugDevelopment

Every Bag of Hazardous Medical Waste Starts With a Clinical Decision. Every bag of hazardous medical waste exists for a reason. 🔹A clinician chooses a sterile syringe. 🔹A nurse replaces protective gloves. 🔹A laboratory processes another sample. 🔹An operating room opens another sterile package. These decisions are not about generating waste. They are about protecting patients and healthcare professionals. That is why hazardous medical waste should not be viewed as something that simply needs to be "reduced." Much of it is an unavoidable consequence of delivering safe, high-quality care. The real opportunity lies elsewhere: managing that unavoidable waste in the safest, most efficient way possible. ➡️ At Envomed, hazardous medical waste is treated on-site, allowing healthcare facilities to integrate treatment into their daily workflow rather than relying solely on off-site collection and disposal. 🔗 Learn more about on-site medical waste treatment: https://lnkd.in/eZf7GnpJ #Envomed #EnvomedGlobal

Patient perspectives were at the heart of ERS 2026, and this year’s theme of “United for better breathing” spoke to the commitment we all have to ordinary people, whose lives we positively impact through advances in science across respiratory health and care. This responsibility also means not passing the burden of change onto the people at the other end of it. As a CDP 2025 Climate A List organisation, Chiesi is committed to Net Zero by 2035, 15 years ahead of the European Climate Neutrality target, with these targets validated by Science Based Targets Initiative (SBTi).

Join our online Insight Session to discover what separates a promising discovery from a successful therapeutic 👇🏻 Explore the oncology drug development journey, why therapies succeed or fail, and what it takes to move from scientist to founder. Whether you're new to translational research or considering our Therapeutic Accelerator, you'll gain practical insights to help shape your next steps. 📅 30 September 💻 Online | 1pm-4pm BST 🔗 Register: https://bit.ly/4hbR2wa